Clinical Trial Detail

NCT ID NCT03337724
Title A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer (IPATunity130)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Hoffmann-La Roche
Indications

Her2-receptor negative breast cancer

triple-receptor negative breast cancer

Therapies

Ipatasertib + Paclitaxel

Paclitaxel

Age Groups: adult senior

Additional content available in CKB BOOST